Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ Transplants (original) (raw)
Cytomegalovirus in transplantation ? challenging the status quo
Hans Schlitt
Clinical Transplantation, 2007
View PDFchevron_right
Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation
Mohammad Shawaqfeh
Transplant Research and Risk Management
View PDFchevron_right
Prevention and treatment of cytomegalovirus infection in organ transplant recipients
Ron Shapiro
Transplant Infectious Disease, 1999
View PDFchevron_right
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy
Biju George
Transplant Infectious Disease, 2010
View PDFchevron_right
Effect of Cytomegalovirus (CMV) Serostatus on the Incidence and Virological Features of Active CMV Infection in Allogeneic Stem Cell Transplant Recipients
Carlos Solano
Clinical Infectious Diseases, 2011
View PDFchevron_right
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
Wolfgang Preiser
British Journal of Haematology, 2000
View PDFchevron_right
The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients
Amrita Prayag
The Journal of Infectious Diseases, 2018
View PDFchevron_right
Preemptive Therapy for the Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: Our Preliminary Experience
Ernesto Lage
Transplantation Proceedings, 2009
View PDFchevron_right
Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Michael Maris
Biology of Blood and Marrow Transplantation, 2009
View PDFchevron_right
Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy
Pilar Blanco Lobo
Transplant International, 2014
View PDFchevron_right
Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients
Javier Bueno
Pediatric Drugs, 2002
View PDFchevron_right
The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients
Martin Prieto
Transplantation reviews (Orlando, Fla.), 2014
View PDFchevron_right
Management of CMV infections: recommendations from the infectious diseases working party of the EBMT
Patricia Ribaud
Bone Marrow Transplantation, 2004
View PDFchevron_right
New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Party of EBMT
Dina Averbuch
Research Square (Research Square), 2022
View PDFchevron_right
Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies
John Wingard
Biology of Blood and Marrow Transplantation, 2003
View PDFchevron_right
New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT
Rafael de la Camara
Bone Marrow Transplantation
View PDFchevron_right
Status of Cytomegalovirus Prevention and Treatment in 2000
Don Diamond
Hematology, 2000
View PDFchevron_right
Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies
Aneela Majeed
Transplantation Proceedings, 2018
View PDFchevron_right
Results of Different Strategies for Reducing Cytomegalovirus-Associated Mortality in Allogeneic Stem Cell Transplant RECIPIENTS1
Stefan Carlens
Transplantation, 1998
View PDFchevron_right
Kinetics of cytomegalovirus (CMV) pp65 and IE1-specific IFNγ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection
Carlos Solano
Journal of Medical Virology, 2010
View PDFchevron_right
Oral Versus Intravenous Anti-CMV Preemptive Strategies in Allogeneic Stem Cell Transplant Patients with CMV Reactivation: Experience from the National Center of Bone Marrow Transplantation, Tunis, Tunisia
Tarek Ben Othman
OBM transplantation, 2023
View PDFchevron_right
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
Giovanni Strippoli
Nephrology, 2013
View PDFchevron_right
Influence of Cytomegalovirus Disease in Outcome of Solid Organ Transplant Patients
Tomas Pumarola
Transplantation Proceedings, 2011
View PDFchevron_right
Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens
Suparno Chakrabarti
Bone Marrow Transplantation, 2004
View PDFchevron_right
Impact of Current Transplantation Management on the Development of Cytomegalovirus Disease after Renal Transplantation
Miguel Montejo
Clinical Infectious Diseases, 2008
View PDFchevron_right
Impact of Current Transplantation Management on the Development of Cytomegalovirus Disease after Renal Transplantation. Commentary
Patricia Muñoz, Marino Blanes
Clinical Infectious Diseases an Official Publication of the Infectious Diseases Society of America, 2008
View PDFchevron_right